SCHEMBL6175183

SCHEMBL6175183

Cc1nnnn1-c1ccc(C(=CCC2CCCC2)C(=O)Nc2nccs2)cc1C(F)(F)F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCK P35557 4/20 0.38
POLB P06746 1/20 0.38
EPHX2 P34913 1/20 0.38
MEN1 O00255 5/20 0.36
KMT2A Q03164 5/20 0.36
USP2 O75604 3/20 0.36
LMNA P02545 3/20 0.36
HSD17B10 Q99714 3/20 0.36
MAPT P10636 2/20 0.36
HTT P42858 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
TSHR P16473 1/20 0.36
STAT3 P40763 1/20 0.36
ALDH1A1 P00352 4/20 0.36
NPSR1 Q6W5P4 1/20 0.36
MAPK14 Q16539 1/20 0.34
KCNH2 Q12809 1/20 0.34
TP53 P04637 1/20 0.34
GAA P10253 1/20 0.34
ALOX15 P16050 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2657964 1.00 GCK (0.38) GCKPOLBEPHX2MEN1KMT2A
SCHEMBL6173654 0.90 GCK (0.46) GCKPOLBEPHX2MEN1KMT2A
SCHEMBL6173642 0.90 GCK (0.46) GCKPOLBEPHX2MEN1KMT2A
SCHEMBL6175122 0.84 NOTUM (0.35) KMT2ALMNA
SCHEMBL6175131 0.84 NOTUM (0.35) KMT2ALMNA
SCHEMBL6176744 0.83 SMURF1 (0.36) EPHX2LMNA
SCHEMBL6176734 0.83 SMURF1 (0.36) EPHX2LMNA
SCHEMBL2646038 0.80 KCNH2 (0.50) GCKPOLBEPHX2MEN1KMT2A
SCHEMBL2646037 0.80 KCNH2 (0.50) GCKPOLBEPHX2MEN1KMT2A
SCHEMBL6172662 0.79 KCNH2 (0.56) GCKKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1311504-B1 TETRAZOLYL-PHENYL ACETAMIDE GLUCOKINASE ACTIVATORS HOFFMANN LA ROCHE (CH) 2005-06-15 EP disclosed
US-6441180-B1 TO INCREASE INSULIN SECRETION, WHICH MAKES THEM USEFUL FOR TREATING TYPE II DIABETES HOFFMANN-LA ROCHE INC. 2002-08-27 US disclosed
US-20020065275-A1 Tetrazolyl-phenyl actamide glucokinase activators SIDDURI ACHYUTHARAO (US) 2002-05-30 US disclosed
US-6388088-B1 ANTIDIABETIC AGENTS HOFFMAN-LA ROCHE INC. 2002-05-14 US disclosed
US-6369232-B1 ANTIDIABETIC AGENTS HOFFMANN-LA ROCHE INC. 2002-04-09 US disclosed
US-20020035267-A1 Tetrazolyl-phenyl acetamide glucokinase activators SIDDURI ACHYUTHARAO (US) 2002-03-21 US disclosed
US-20020035266-A1 Tetrazolyl-phenyl acetamide glucokinase activators SIDDURI ACHYUTHARAO (US) 2002-03-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020035267-A1 Tetrazolyl-phenyl acetamide glucokinase activators GCKR, GCK, PCK1 GCK 2/4885POLB 4326/4885EPHX2 4498/4885
US-20020035266-A1 Tetrazolyl-phenyl acetamide glucokinase activators GCKR, GCK, PCK1 GCK 2/4885POLB 4326/4885EPHX2 4498/4885
US-20020065275-A1 Tetrazolyl-phenyl actamide glucokinase activators GCKR, GCK, PFKL GCK 2/4885POLB 4478/4885EPHX2 4781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.